Skip to main content

Table 1 Patient characteristics

From: Classification of ductal carcinoma in situ by gene expression profiling

In situ samples Invasive samples
Differentiation Number (percentage) Histological grade Number (percentage)
Well 6 (15%) 1 5 (12.5%)
Intermediately 18 (45%) 2 11 (27.5%)
Poorly 14 (35%) 3 24 (60%)
Good/poor component 1 (2.5%)   
LCIS 1 (2.5%)   
IHC   IHC  
ER-positive 28 (70%)a ER-positive 22 (55%)c
PR-positive 24 (60%)a PR-positive 19 (47.5%)d
Her2/neu-positive (3+) 12 (30%)b Her2/neu-positive (3+) 4 (10%)d
p53-positive 11 (27.5%)b p53-positive 9 (22.5%)d
Tumour detection    
Palpation 17 (42.5%)   
Microcalcifications 18 (45%)   
Others 5 (12.5%)   
Tumour diameter (mm)    
Range 10 to 80   
Median 45   
Average 42.8   
Treatment    
Mastectomy 24 (60%)   
Breast conserving treatment 6 (15%)   
Local excision followed by mastectomy 10 (25%)   
  1. a5% not assessable, b2.5% not assessable, c27.5% not assessable, d30% not assessable. ER, oestrogen receptor; IHC, immunohistochemistry; LCIS, lobular carcinoma in situ; PR, progesterone receptor.